C-reactive protein and nitric oxide level in patients with white coat hypertension

Blood Pressure

Volumn 21, Issue 5, 2012, Pages 281-285

  Guven, Aytekin ^a   Tolun, Fatma ^b   Caliskan, Mustafa ^a   Ciftci, Ozgur ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Endothelium; Hypertension; Nitric oxide; White coat hypertension

Indexed keywords

C REACTIVE PROTEIN; NITRIC OXIDE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; WHITE COAT HYPERTENSION;

ADULT; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; NITRIC OXIDE; WHITE COAT HYPERTENSION;

EID: 84866941173     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2011.649541     Document Type: Article

References (40)

1. Y, Curgunlu A, Altni ik S, Ertürk N, Vehid S, Mihmanli I, et al. Target organ damage and changes in arterialcompliance in white coat hypertension. Is white coatinnocentBlood Press. 2003;12:307-313.
2. Polonia JJ, Gama GM, Silvia A, Amaral C, Martins LR, Bertequini SE. Sequential follow-up clinic an ambulatoryblood pressure evaluation in a low risk population of whitecoathypertensive patients and in normotensives. BloodPressure Monitoring. 2005;10:57-64.
3. Marchi-Alves LM, Carnio EC. Is there any correlationbetween insulin resistance and nitrate plasma concentrationin white coat hypertensive patients? Cardiol Res Pract. 2009;2009:376735.
4. Pierdomenico SD, Bucci A, Costantini F, Lapenna D, Cuccurullo F, Mezzetti A. Twenty-four-hour autonomicnervous function is sustained and ' white coat ' hypertension. Am Heart J. 2000;140:672-677.
5. Bian K, Doursout MF, Murad F. Vascular system: Role ofnitric oxide in cardiovascular diseases. J Clin Hypertens. 2008;10:304-310.
6. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
7. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individualswith essential hypertension. Hypertension. 1997;30:405-408.
8. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet. 1997;349:837-842.
9. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role ofendothelium-derived nitric oxide in in the abnormal endothelium-dependent vascular relaxation in patients with essentialhypertension. Circulation. 1993;87:1468-1474.
10. Iiyama K, Nagano M, Yo Y, et al. Impaired endothelial functionwith essential hypertension assessed by ultrasonography. Am Heart J. 1996;132:779-782.
11. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide isresponsible for flow-dependent dilatation of human peripheralconduit arteries in vivo. Circulation. 1995;91:1314-1319.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, HennekensCH. Inflammation, aspirin, and the risk of cardiovasculardisease in apparently healthy men. N Engl J Med. 1997;336:973-979.
13. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, asensitive marker of inflammation, predicts future risk of coronaryheart disease in initially healthy middle-aged men:Results from the MONICA (Monitoring Trends and Determinantsin Cardiovascular Disease) Augsburg Chort Study, 1984 to 1992. Circulation. 1999;99:237-242.
14. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship ofC-reactive protein to risk of cardiovascular disease in theelderly: Results from the Cardiovascular Health Study andRural Health Promotion Project. Arterioscler Thromb VascBiol. 1997;17:1121-1127.
15. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactiveprotein and other markers of inflammation in the predictionof cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
16. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparisonof C-reactive protein and low-density lipoproteincholesterol levels in the prediction of first cardiovascularevents. N Engl J Med. 2002;347:1557-1565.
17. Ford ES, Giles WH. Serum C-reactive protein and fibrinogenconcentrations and self-reported angina pectoris andmyocardial infarction: Findings from National Health andNutrition Examination Survey III. J Clin Epidemiol. 2000;53:95-102.
18. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationship among circulating interleukin-6, C-reactiveprotein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22:1668-1673.
19. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy:C-reactive protein attenuates nitric oxide production andinhibits angiogenesis. Circulation. 2002;106:913-919.
20. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstrationthat C-reactive protein decreases eNOS expressionand bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
21. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonismand interleukin-6 inhibition attenuate the proatherogeniceffects of C-reactive protein. Circulation. 2002;105:1890-1896.
22. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogenactivator inhibitor-1 expression and activity inhuman aortic endothelial cells: Implications for the metabolicsyndrome and atherothrombosis. Circulation. 2003;107:398-404.
23. Cortas NK, Wakid NW. Determination of inorganic nitrate inserum and urine by a kinetic cadmium-reduction method. Clin Chem. 1990;36:1440-1443.
24. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite andnitrate determinations in plasma: A critical evaluation. ClinChem. 1995;41:892-896.
25. Pepys MB, Hirschfield GM. C-reactive protein: A criticalupdate. J Clin Invest. 2003;111:1805-1812.
26. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognosticvalue of C-reactive protein and serum amyloid a protein insevere unstable angina. N Engl J Med. 1994;331:417-424.
27. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de LooJC. Hemostatic factors and the risk of myocardial infarctionor sudden death in patients with angina pectoris. EuropeanConcerted Action on Thrombosis and Disabilities AnginaPectoris Study Group. N Engl J Med. 1995;332:635-641.
28. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, PepysMB. Production of C-reactive protein and risk of coronaryevents in stable and unstable angina. European ConcertedAction on Thrombosis and Disabilities Angina Pectoris StudyGroup. Lancet. 1997;349:462-466.
29. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive proteinand other circulating markers of inflammation in theprediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
30. Verma S, Anderson TJ. The ten most commonly asked questionsabout endothelial function in cardiology. Cardiol Rev. 2001;9:250-252.
31. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulatesangiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
32. Ross R. Atherosclerosis: An inflammatory disease. N Engl JMed. 1999;340:115-126.
33. Todd ME. Hypertensive structural changes in blood vessels:Do endothelial cells hold the key? Can J Physiol Pharmacol. 1992;70:536-551.
34. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship ofC-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and theRural Health Promotion Project. Arterioscler Thromb VascBiol. 1997;17:1121-1127.
35. Glen SK, Elliott HL, Curzio JL, Lees KR, Reid JL. Whitecoathypertension as a cause of cardiovascular dysfunction. Lancet. 1996;348:654-657.
36. Palatini P, Mormino P, Santonastaso M, et al. Target-organdamage in stage I hypertensive subjects with white coat andsustained hypertension: Results from the HARVEST study. Hypertension. 1998;31:57-63.
37. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome inwhite-coat versus sustained mild hypertension: A 10-yearfollow-up study. Circulation. 1998;98:1892-1897.
38. Pierdomenico SD, Cipollone F, Lapenna D, Bucci A, CuccurulloF, Mezzetti A. Endothelial function in sustained andwhite coat hypertension. Am J Hypertens. 2002;15:946-95239.
39. Conen D, Dieterle T, Utech K, Rimner M, Martina B. C-reactive protein and B-type natriuretic peptides in nevertreatedwhite coat hypertensives. Hypertens Res. 2006;29:411-415.
40. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactiveprotein concentrations in never-treated hypertension: Therole of systolic and pulse pressures. J Hypertens. 2003;21:1841-1846.